A new finance chief will take over on Monday at Becton Dickinson & Co. (NYSE:BDX), the company announced this week. BD nabbed Christopher Reidy from his former gig as CFO at ADP Corporation. Reidy has also worked in executive finance roles at NBA Properties Inc. and AT&T.
BD’s Suketu Upadhyay, who has worked as CFO since Nov. 2012, will not leave the company, but he will step down a rung to work as senior VP of finance.
"It is a pleasure to welcome Chris to our executive management team,” CEO Vincent Forlenza said in prepared remarks. “He possesses significant financial and operational expertise, complemented by strategic and execution skills.
Arch Therapeutics reports more executive shuffling following reverse merger
Arch Therapeutics continued to shuffle its leadership following a reverse merger, announcing a new COO and CFO this week. Both newly minted finance chief Alan Barber and operations chief William Cotter hail from Arch Biosurgery, now a subsidiary following last month’s deal.
Barber previously worked at Biotrove, Omnisonics Medical and Innovation Chain. Cotter also comes from a long career in medical devices, with former work experience at Cohera Medical, Helicos Biosciences, Closure Medical Corporation, Sanofi Diagnostics Pasteur, Genetic Systems Corporation and Advanced Technology Laboratories, according to a press release.
Cambridge, Mass.-based Arch Therapeutics, which adopted the business plan of the newly acquired subsidiary, took on new CEO, director and board chairman last week.
CytoSorbents pulls in medical marketing PhD as scientific affairs director
CytoSorbents hired a new scientific affairs director for its European subsidiary, CytoSorbents Europe GmbH. Dr. Rainer Kosanke previously worked as marketing as deputy sales director at B.R.A.H.M.S AG, which was acquired in 2009 by Thermo Fisher (NYSE:TMO).
At CytoSorbents Kosanke will immediately take over the ongoing trial for a sepsis blood purification treatment called the CytoSorb Dosing Study, according to a press release.
Company sales VP Christian Steiner called Kosanke a "perfect fit" for CytoSorbents, thanks to his understanding of sepsis and his experience working with key opinion leaders in the European sales territory.